Pro-Pharmaceuticals, Inc. To Present At Annual Glycobiology Conference; Targeting Tumor Lectins, DAVANAT(R) Shows Promising Results In Phase I Trial With 5-FU Refractory Patients

NEWTON, Mass.--(BUSINESS WIRE)--Nov. 11, 2005--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, today announced that Eliezer Zomer, Ph.D., Executive Vice President of Product Development and Manufacturing, Pro-Pharmaceuticals, will present in an abstract and a poster, "Targeting Tumor Lectins, Galactomannan Derivative Shows Promising Results in Pre-Clinical Studies and Phase I Clinical Trial With 5-FU Refractory Patients," at the Annual Conference of the Society for Glycobiology, November 9-12, at The Boston Park Plaza Hotel, Boston, Mass.